Valuation: 3billion, Inc.

Market Cap 172B 124M 107M 100M 91.36M 172M 11.84B 173M 1.18B 459M 5.97B 466M 456M 19.79B P/E 2025
-107x
P/E 2026 * -
Enterprise Value 155M 112K 96.11K 90.21K 82.39K 155K 10.68M 156K 1.07M 414K 5.39M 420K 411K 17.85M EV / Sales 2025
49x
EV / Sales 2026 * -
Free-Float
75.48%
Yield 2025 *
-
Yield 2026 * -
1 day-0.55%
1 week-7.99%
Current month+5.25%
1 month-3.05%
3 months-46.91%
6 months-64.22%
Current year-70.32%
1 week 5,140
Extreme 5140
6,140
1 month 4,260
Extreme 4260
6,660
Current year 4,260
Extreme 4260
18,690
1 year 4,260
Extreme 4260
20,100
3 years 3,025
Extreme 3025
20,100
5 years 3,025
Extreme 3025
20,100
10 years 3,025
Extreme 3025
20,100
Manager TitleAgeSince
Chief Executive Officer 45 10/10/2016
Director of Finance/CFO 46 01/10/2020
Chief Tech/Sci/R&D Officer 46 01/08/2018
Director TitleAgeSince
Director/Board Member 45 10/10/2016
Director/Board Member 44 10/10/2016
Director/Board Member 44 18/11/2020
Date Insider Type Main position Quantity % Market Cap.
16/4/25 Others

Chief Financial Officer

44,000 0.1387%
7/3/25 Fiscal year

Chief Financial Officer

40,000 0.1262%
7/3/25 Fiscal year 10,000 0.0316%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%-7.99%-11.60% - 124M
-0.34%+6.51%+106.47%+324.68% 4.19B
-4.27%+14.94%+219.37%+31.38% 3.82B
+0.57%+8.87%+49.88%+74.16% 3.54B
+0.31%+10.35%+299.69%+483.73% 2.63B
-2.91%+4.01%-26.20%-20.95% 2.32B
+0.79%+4.01%+32.48% - 1.5B
-1.11%+55.05%+270.83%-14.42% 1.34B
-2.18%+3.80%+19.81%+45.60% 1.03B
+1.68%+22.01%+34.48%+180.72% 678M
Average -0.70%+13.70%+99.52%+138.11% 2.12B
Weighted average by Cap. -1.00%+13.31%+124.73%+159.31%

Financials

2025 2026 *
Net sales 10.8B 7.79M 6.69M 6.28M 5.73M 10.82M 743M 10.87M 74.26M 28.78M 375M 29.25M 28.61M 1.24B -
Net income -5.8B -4.18M -3.59M -3.37M -3.08M -5.81M -399M -5.84M -39.88M -15.46M -201M -15.71M -15.37M -667M -
Net Debt -16.9B -12.19M -10.46M -9.82M -8.97M -16.93M -1.16B -17.01M -116M -45.03M -586M -45.77M -44.77M -1.94B -
Logo 3billion, Inc.
3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.
Employees
-
Date Price Change Volume
26/08/26 ₩5,410.00 0.00% 51,563
25/08/26 ₩5,410.00 -0.55% 70,817
24/08/26 ₩5,440.00 +0.37% 67,644
21/08/26 ₩5,420.00 -6.23% 95,538
20/08/26 ₩5,780.00 -0.17% 124,490

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A394800 Stock